Tags

Type your tag names separated by a space and hit enter

Increased Alzheimer's disease neuropathology is associated with type 2 diabetes and ApoE ε.4 carrier status.
Curr Alzheimer Res 2013; 10(6):654-9CA

Abstract

BACKGROUND

Past studies investigating the association between Alzheimer's disease (AD) pathology and diabetes mellitus type 2 (DM2) have provided conflicting results. While several studies indicate that subjects with comorbid AD and DM2 have less AD pathology, others have found no significant differences in AD pathology between the two groups. Other studies have indicated that individuals with AD and DM2 have significantly greater neuropathology than AD individuals who do not have DM2. Additional research has demonstrated that ApoE ε4 carriers with AD and DM2 have significantly greater pathology than ApoE ε4 non-carriers.

METHODS

Data on clinically and pathologically diagnosed Alzheimer's disease cases (NINDS-ADRDA clinically and NIA Reagan intermediate or high pathologically) with DM2 (n= 40) and those without DM2 (n= 322) from the Banner Sun Health Research Institute Brain and Body Donation Program were obtained for this study. Plaque and tangle scores from the frontal, parietal, temporal, entorhinal and hippocampal regions were compared between the DM2+ and DM2 - groups. In addition, total plaque count, total tangle count, and Braak scores were also compared between groups. Similar analyses were conducted to determine the effect of ApoE ε4 carrier status on the neuropathological variables while also accounting for and DM2 status.

RESULTS

The DM2+ and DM2 - groups showed no significant differences on plaque and tangle pathology. Logistic regression analyses, which accounted for the effects of ApoE .ε4 carrier status and age at death, found no association between total plaque [OR 1.05 (0.87, 1.27), p = 0.60] or total tangle [OR 0.97 (0.89, 1.07) p = 0.58] counts and DM2 status. ApoE ε4 carrier status was not significantly associated with DM2 status [.Χ2 = 0.30 (df = 1), p = 0.58]. Within the DM2+ group, significantly greater plaque and tangle pathology was found for ApoE ε4 carriers in relation to DM2+ ApoE ε4 non-carriers.

CONCLUSION

Overall, the presence of DM2 does not affect plaque and tangle burden in a sample of clinically and pathologically confirmed AD cases. Among AD individuals with DM2, those who are ApoE ε4 carriers had significantly greater neuropathology than those who do not carry an ApoE ε4 allele. Positive DM2 status appears to exacerbate AD neuropathology in the presence of ApoE ε4.

Authors+Show Affiliations

The Cleo Robert Center for Clinical Research, Banner Sun Health Research Institute, Sun City, AZ 85351, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23627755

Citation

Malek-Ahmadi, Michael, et al. "Increased Alzheimer's Disease Neuropathology Is Associated With Type 2 Diabetes and ApoE Ε.4 Carrier Status." Current Alzheimer Research, vol. 10, no. 6, 2013, pp. 654-9.
Malek-Ahmadi M, Beach T, Obradov A, et al. Increased Alzheimer's disease neuropathology is associated with type 2 diabetes and ApoE ε.4 carrier status. Curr Alzheimer Res. 2013;10(6):654-9.
Malek-Ahmadi, M., Beach, T., Obradov, A., Sue, L., Belden, C., Davis, K., ... Sabbagh, M. N. (2013). Increased Alzheimer's disease neuropathology is associated with type 2 diabetes and ApoE ε.4 carrier status. Current Alzheimer Research, 10(6), pp. 654-9.
Malek-Ahmadi M, et al. Increased Alzheimer's Disease Neuropathology Is Associated With Type 2 Diabetes and ApoE Ε.4 Carrier Status. Curr Alzheimer Res. 2013;10(6):654-9. PubMed PMID: 23627755.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Increased Alzheimer's disease neuropathology is associated with type 2 diabetes and ApoE ε.4 carrier status. AU - Malek-Ahmadi,Michael, AU - Beach,Thomas, AU - Obradov,Aleksandra, AU - Sue,Lucia, AU - Belden,Christine, AU - Davis,Kathryn, AU - Walker,Douglas G, AU - Lue,LihFen, AU - Adem,Abdu, AU - Sabbagh,Marwan N, PY - 2013/03/31/received PY - 2013/04/24/revised PY - 2013/02/13/accepted PY - 2013/5/1/entrez PY - 2013/5/1/pubmed PY - 2014/4/12/medline SP - 654 EP - 9 JF - Current Alzheimer research JO - Curr Alzheimer Res VL - 10 IS - 6 N2 - BACKGROUND: Past studies investigating the association between Alzheimer's disease (AD) pathology and diabetes mellitus type 2 (DM2) have provided conflicting results. While several studies indicate that subjects with comorbid AD and DM2 have less AD pathology, others have found no significant differences in AD pathology between the two groups. Other studies have indicated that individuals with AD and DM2 have significantly greater neuropathology than AD individuals who do not have DM2. Additional research has demonstrated that ApoE ε4 carriers with AD and DM2 have significantly greater pathology than ApoE ε4 non-carriers. METHODS: Data on clinically and pathologically diagnosed Alzheimer's disease cases (NINDS-ADRDA clinically and NIA Reagan intermediate or high pathologically) with DM2 (n= 40) and those without DM2 (n= 322) from the Banner Sun Health Research Institute Brain and Body Donation Program were obtained for this study. Plaque and tangle scores from the frontal, parietal, temporal, entorhinal and hippocampal regions were compared between the DM2+ and DM2 - groups. In addition, total plaque count, total tangle count, and Braak scores were also compared between groups. Similar analyses were conducted to determine the effect of ApoE ε4 carrier status on the neuropathological variables while also accounting for and DM2 status. RESULTS: The DM2+ and DM2 - groups showed no significant differences on plaque and tangle pathology. Logistic regression analyses, which accounted for the effects of ApoE .ε4 carrier status and age at death, found no association between total plaque [OR 1.05 (0.87, 1.27), p = 0.60] or total tangle [OR 0.97 (0.89, 1.07) p = 0.58] counts and DM2 status. ApoE ε4 carrier status was not significantly associated with DM2 status [.Χ2 = 0.30 (df = 1), p = 0.58]. Within the DM2+ group, significantly greater plaque and tangle pathology was found for ApoE ε4 carriers in relation to DM2+ ApoE ε4 non-carriers. CONCLUSION: Overall, the presence of DM2 does not affect plaque and tangle burden in a sample of clinically and pathologically confirmed AD cases. Among AD individuals with DM2, those who are ApoE ε4 carriers had significantly greater neuropathology than those who do not carry an ApoE ε4 allele. Positive DM2 status appears to exacerbate AD neuropathology in the presence of ApoE ε4. SN - 1875-5828 UR - https://www.unboundmedicine.com/medline/citation/23627755/Increased_Alzheimer's_disease_neuropathology_is_associated_with_type_2_diabetes_and_ApoE_ε_4_carrier_status_ L2 - http://www.eurekaselect.com/113170/article DB - PRIME DP - Unbound Medicine ER -